Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on oncology that entered public markets through a de-SPAC merger with Panacea Acquisition Corp. II, a blank-check vehicle sponsored by Panacea Capital Management that completed its IPO in 2021. The combined company has traded on the NYSE under the NUVB ticker since the transaction closed in early 2022, with its pipeline targeting novel cancer therapeutics across multiple tumor types. The company filed an 8-K current report with the SEC on May 23, 2025, fulfilling its ongoing disclosure obligations as a post-merger public operating entity in the biopharmaceutical sector. Sign up at SpacDesk for the full filing history, transaction data, and real-time monitoring on NUVB and hundreds of other SPAC-linked companies.